TNF and rheumatoid arthritis: Tumor necrosis factor inhibitor (TNFI) infliximab (IFX: a chimeric mouse/human anti‐TNF‐α monoclonal antibody) proved beneficial in suppressing periodontal diseases in patients with RA (Pers et al., 2008; Mayer et al., 2009; Mayer et al., 2013).